Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
21.06
+0.31 (1.49%)
At close: Nov 4, 2026, 4:00 PM EST
21.99
+0.93 (4.42%)
After-hours: Nov 4, 2026, 7:58 PM EST
Takeda Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 40,795 | -152,390 | 107,928 | 144,067 | 317,017 | 230,059 |
Depreciation & Amortization | 639,438 | 678,583 | 720,982 | 728,002 | 664,400 | 583,151 |
Other Amortization | 42,544 | 42,544 | 40,414 | - | - | - |
Loss (Gain) From Sale of Assets | 4,649 | -15,197 | -5,703 | -1,780 | -6,797 | -7,174 |
Asset Writedown & Restructuring Costs | 89,428 | 145,716 | 106,529 | 150,017 | 64,394 | 54,515 |
Loss (Gain) From Sale of Investments | 47 | 1,006 | -602 | 20,757 | 3,991 | -11,195 |
Loss (Gain) on Equity Investments | -434 | 2,177 | 3,986 | -6,473 | 8,630 | 15,367 |
Stock-Based Compensation | 75,106 | 72,775 | 72,867 | 70,871 | 60,672 | 43,374 |
Other Operating Activities | -53,686 | 66,312 | 70,153 | -133,114 | -109,887 | 116,403 |
Change in Accounts Receivable | -138,772 | -70,166 | -58,959 | 15,104 | 75,127 | 127,294 |
Change in Inventory | -94,915 | -61,293 | -34,973 | -115,743 | -79,155 | -46,148 |
Change in Accounts Payable | -5,544 | -3,150 | -7,118 | -9,895 | -84,804 | 125,157 |
Change in Other Net Operating Assets | 281,014 | 334,514 | 41,678 | -145,469 | 63,568 | -107,698 |
Operating Cash Flow | 879,670 | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 |
Operating Cash Flow Growth | -26.67% | -1.49% | 47.58% | -26.69% | -13.00% | 11.10% |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -186,496 | -176,003 | -200,795 | -175,420 | -140,657 | -123,252 |
Sale of Property, Plant & Equipment | 1,528 | 6,454 | 78 | 8,606 | 962 | 1,815 |
Cash Acquisitions | - | - | - | - | - | -49,672 |
Divestitures | 26,416 | 33,325 | 20,556 | 19,959 | 7,958 | 28,196 |
Sale (Purchase) of Intangibles | -255,502 | -234,930 | -147,046 | -305,310 | -493,032 | -62,785 |
Investment in Securities | 3,629 | -8,607 | -11,407 | 1,255 | 12,103 | 8,580 |
Other Investing Activities | 13,836 | 10,620 | -28,446 | -12,952 | 5,564 | -1,007 |
Investing Cash Flow | -396,589 | -369,141 | -367,060 | -463,862 | -607,102 | -198,125 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | - | 27,490 | 277,000 | 40,000 | - |
Long-Term Debt Issued | - | 586,060 | 1,024,460 | 100,000 | 75,000 | 249,334 |
Total Debt Issued | 60,000 | 586,060 | 1,051,950 | 377,000 | 115,000 | 249,334 |
Short-Term Debt Repaid | - | -341,780 | - | - | - | -2 |
Long-Term Debt Repaid | - | -243,204 | -1,366,264 | -375,487 | -400,071 | -849,809 |
Lease Payments | -42,139 | -42,772 | -45,174 | -54,586 | -43,401 | -39,694 |
Total Debt Repaid | -356,810 | -584,984 | -1,366,264 | -375,487 | -400,071 | -849,811 |
Net Debt Issued (Repaid) | -296,810 | 1,076 | -314,314 | 1,513 | -285,071 | -600,477 |
Repurchase of Common Stock | -1,007 | -51,603 | -51,860 | -2,326 | -26,929 | -77,531 |
Common Dividends Paid | -315,684 | -311,901 | -302,498 | -287,188 | -279,416 | -283,665 |
Other Financing Activities | -147,808 | -134,392 | -82,753 | -66,415 | -117,732 | -108,592 |
Financing Cash Flow | -761,309 | -496,820 | -751,425 | -354,416 | -709,148 | -1,070,265 |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Foreign Exchange Rate Adjustments | 15,276 | 34,472 | -11,385 | 26,204 | 22,929 | 28,758 |
Miscellaneous Cash Flow Adjustments | -1 | -1 | 1 | - | - | - |
Net Cash Flow | -262,953 | 209,941 | -72,687 | -75,730 | -316,165 | -116,527 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 693,174 | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | -31.89% | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
Free Cash Flow Margin | 14.77% | 19.21% | 18.69% | 12.69% | 20.77% | 28.02% |
Free Cash Flow Per Share | 437.79 | 549.46 | 533.47 | 342.28 | 532.85 | 633.95 |
Levered Free Cash Flow | 681,377 | 672,783 | 735,617 | 121,361 | 480,297 | 929,111 |
Unlevered Free Cash Flow | 818,613 | 765,360 | 817,171 | 193,481 | 553,405 | 1,005,631 |
Free Cash Flow After Leases | 651,035 | 822,656 | 811,213 | 486,338 | 793,098 | 960,159 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 135,531 | 121,380 | 112,984 | 100,375 | 108,555 | 108,207 |
Cash Income Tax Paid | 159,530 | 172,562 | 150,413 | 202,039 | 185,966 | 140,423 |
Change in Working Capital | 41,783 | 199,905 | -59,372 | -256,003 | -25,264 | 98,605 |